Patients with high-risk melanoma had better quality of life on pembrolizumab than on standard immunotherapy regimens
Patients with high-risk stage III-IV melanoma who received pembrolizumab after their surgery reported a better quality of life than patients who received the previous standard-of-care treatment with either ipilimumab or high-dose ...
Nov 23, 2022
0
4